HomePageSlides

Slide Title	Slide Description	Slide Image	Slide Number	Read More Link
NIH commitment to transparency on research involving potential pandemic pathogens	NIH takes the need to ensure the safety of the public very seriously. We believe the HHS Framework process strikes the right balance of rigorous oversight with the advancement of the important science necessary to prevent and treat infectious diseases.	H5N1. Image courtesy of CDC Public Health Image Library	2	View the NIH statement
Two Research Projects Reviewed Under Department of Health and Human Services Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens	Under the HHS P3CO Framework, the HHS P3CO Review Group determined that, in the case of both research proposals, the research is acceptable for HHS funding with recommended changes to increase the potential benefits while decreasing risks; suggested changes were included as terms and conditions of the awards.	lab tech	2	Learn more about the approval
NIH Lifts Funding Pause on Gain-of-Function Research	The National Institutes of Health announced that it is lifting a funding pause dating back to October 2014 on gain-of-function (GOF) experiments involving influenza, SARS, and MERS viruses.	lab worker	3	Read the NIH Director's Statement
Notice Announcing the Removal of the Funding Pause for Gain-of-Function Research Projects	The National Institutes of Health has removed the funding pause on the provision of new or continuation funding for gain-of-function research projects.	lab hood	4	Read the Official Notice
Review and Revision of the Screening Framework Guidance for Providers of Synthetic Double-Stranded DNA	ASPR is soliciting feedback on whether and, if so, how the Screening Framework Guidance for Providers of Synthetic Double-Stranded DNA should be modified to address new and emerging challenges. We are seeking public input on changes that would either expand or limit the following areas: scope of the Guidance; sequence screening; biosecurity measures; customer screening; minimizing burden of the Guidance; technologies subject to the Guidance; and comments on other related issues. The deadline for public comments is October 25	DNA	1	Learn More and Submit Comments

HomePageSlides // <![CDATA[ _spBodyOnLoadFunctionNames.push("setupPageDescriptionCallout"); // ]]>